

## Selected publications

Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D, Kuhn AN, Omokoko T, Kranz LM, Diken M, Kreiter S, Haas H, Attig S, Rae R, Cuk K, Kemmer-Brück A, Breitzkreuz A, Tolliver C, Caspar J, Quinkhardt J, Hebich L, Stein M, Hohberger A, Vogler I, Liebig I, Renken S, Sikorski J, Leierer M, Müller V, Mitzel-Rink H, Miederer M, **Huber C**, Grabbe S, Utikal J, Pinter A, Kaufmann R, Hassel JC, Loquai C, Türeci Ö.

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.

**Nature**. 2020 Sep;585(7823):107-112.

Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, **Huber C**, Krivoschik A, Arozullah A, Park JW, Schuler M.

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.

**Ann Oncol**. 2019 Sep 1;30(9):1487-1495. doi: 10.1093/annonc/mdz199.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, **Huber C**, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

**Nature**. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19.

Ugur Sahin, Martin Schuler, Heike Richly, Stefan Bauer, Anna Krilova, Tobias Dechow, Markus Jerling, Magdalena Utsch, Christoph Rohde, Karl Dhaene, **Christoph Huber**, Özlem Türeci, A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer

**Europ.J.Cancer** 100 82018, 17-26

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M<sup>1</sup>, Albrecht C, Paruzynski A, Kuhn AN<sup>1</sup>, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitzkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksman O, Brück AK, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Höller C, Utikal J, **Huber C**, Loquai C, Türeci Ö. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.

**Nature**. 2017 Jul 13;547(7662):222-226

Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanesian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe S, **Huber C**, Türeci Ö, Sahin U. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.

**Nature**. 2016 Jun 1;534(7607):396-401

Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, **Huber C**, Türeci Ö, Sahin U. Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

**Nature**. 2015 Apr 30;520(7549):692-6.

Britten CM, Singh-Jasuja H, Flamion B, Hoos A, **Huber C**, Kallen KJ, Khleif SN, Kreiter S, Nielsen M, Rammensee HG, Sahin U, Hinz T, Kalinke U. The regulatory landscape for actively personalized cancer immunotherapies.

**Nat Biotechnol**. 2013 Oct;31(10):880-2.

Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, Koslowski M, Kuhn AN, Britten CM, **Huber C**, Türeci O, Sahin U.

Exploiting the mutanome for tumor vaccination.

**Cancer Res**. 2012 Mar 1;72(5):1081-91

Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, **Huber C**, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM. T cell assays and MIATA: the essential minimum for maximum impact.

**Immunity**. 2012 Jul 27;37(1):1-2.

Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, **Huber C**, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA.

Cancer classification using the Immunoscore: a worldwide task force.

**J Transl Med**. 2012 Oct 3;10:205.

Hoos A, Britten CM, **Huber C**, O'Donnell-Tormey J.

A methodological framework to enhance the clinical success of cancer immunotherapy.

**Nat Biotechnol**. 2011 Oct 13;29(10):867-70

Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Hüsemann Y, Koslowski M, **Huber C**, Türeci

Ö, Sahin U. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines.  
**Cancer Res.** 2011 Oct 1;71(19):6132-42.

Diken M, Kreiter S, Selmi A, Britten CM, **Huber C**, Türeci Ö, Sahin U.  
Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation.  
**Gene Ther.** 2011 Jul;18(7):702-8. doi: 10.1038/gt.2011.17.

Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, **Huber C**, Türeci O, Sahin U.  
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.  
**Cancer Res.** 2010 Nov 15;70(22):9031-40.

Kuhn AN, Diken M, Kreiter S, Selmi A, Kowalska J, Jemielity J, Darzynkiewicz E, **Huber C**, Türeci O, Sahin U. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo.  
**Gene Ther.** 2010 Aug;17(8):961-71.

Voss RH, Thomas S, Pfirschke C, Hauptrock B, Klobuch S, Kuball J, Grabowski M, Engel R, Guillaume P, Romero P, **Huber C**, Beckhove P, Theobald M.  
Coexpression of the T-cell receptor constant alpha domain triggers tumor reactivity of single-chain TCR-transduced human T cells.  
**Blood.** 2010 Jun 24;115(25):5154-63.

Koslowski M, Türeci O, **Huber C**, Sahin U.  
Selective activation of tumor growth-promoting Ca<sup>2+</sup> channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2.  
**Mol Cancer.** 2009 Sep 25;8:77.

Koslowski M, Türeci O, Biesterfeld S, Seitz G, Huber C, Sahin U. Selective activation of trophoblast-specific PLAC1 in breast cancer by CCAAT/enhancer binding protein {beta} (C/EBP{beta}) isoform 2.  
**J Biol Chem.** 2009 Aug 3.

Frank Breitenbuecher, Boyka Markova, Stefan Kasper, Birgit Carius, Torsten Stauder, Frank D. Böhmer, Kristina Masson, Lars Rönstrand, Christoph Huber, Thomas Kindler, Thomas Fischer\*, A Novel Molecular Mechanism of Primary Resistance to FLT3-Kinase Inhibitors in Acute Myeloid Leukemia,  
**Blood.** 2009 Apr 23;113(17):4063-73.

Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, Huber C, Türeci O.  
Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development.  
**Clin Cancer Res.** 2008 Dec 1;14(23):7624-34

Breitenbuecher F, Schnittger S, Grundler R, Markova B, Carius B, Brecht A, Duyster J, Haferlach T, Huber C, Fischer T. Identification of a novel type of ITD mutations located in non-juxtamembrane domains of the FLT3 tyrosine kinase receptor.

**Blood.** 2008 May 15.

Lipka DB, Hoffmann LS, Heidel F, Markova B, Blum MC, Breitenbuecher F, Kasper S, Kindler T, Levine RL, **Huber C**, Fischer T. LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells.

**Mol Cancer Ther.** 2008 May;7(5):1176-1184.

Hähnel PS, Thaler S, Antunes E, **Huber C**, Theobald M, Schuler M. Targeting AKT Signaling Sensitizes Cancer to Cellular Immunotherapy.

**Cancer Res.** 2008 May 15;68(10):3899-906.

Hartwig UF, Nonn M, Khan S, Link I, **Huber C**, Herr W. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity.

**Biol Blood Marrow Transplant.** 2008 Jan;14(1):99-109.

Voss RH, Willemsen RA, Kuball J, Grabowski M, Engel R, Intan RS, Guillaume P, Romero P, **Huber C**, Theobald M. Molecular Design of the C $\alpha$  Interface Favors Specific Pairing of Introduced TCR $\alpha$  in Human T Cells.

**J Immunol.** 2008 Jan 1;180(1):391-401.

Wölfel C, Lennerz V, Lindemann E, Hess G, Derigs HG, **Huber C**, Herr W, Wölfel T. Dissection and molecular analysis of alloreactive CD8 $^+$  T cell responses in allogeneic haematopoietic stem cell transplantation.

**Cancer Immunol Immunother.** 2007 Nov 15

Marques CA, Hähnel PS, Wölfel C, Thaler S, **Huber C**, Theobald M, Schuler M.

An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression.

**Blood.** 2007 Oct 30;

Koslowski M, Sahin U, Mitnacht-Kraus R, Seitz G, **Huber C**, Türeci O.

A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes.

**Cancer Res.** 2007 Oct 1;67(19):9528-34.

Meyer RG, Korn S, Micke P, Becker K, **Huber C**, Wölfel T, Buhl R. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.

**Lung Cancer.** 2007 Oct;58(1):88-94.

Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, **Huber C**, Loffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A. Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. **Blood**. 2007 Feb 22;

Meyer RG, Britten CM, Wehler D, Bender K, Hess G, Konur A, Hartwig UF, Wehler TC, Ullmann AJ, Gentilini C, Uharek L, **Huber C**, Kolbe K, Herr W. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell depleted reduced-intensity transplantation. **Blood**. 2007 Jan 1;109(1):374-82.

Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, Tureci O, Sahin U. Modification of antigen encoding RNA increases stability, translational efficacy and T-cell stimulatory capacity of dendritic cells. **Blood**. 2006 Dec 15;108(13):4009-17.

Koslowski M, Sahin U, Huber C, Tureci O. The human X chromosome is enriched for germline genes expressed in premeiotic germ cells of both sexes. **Hum Mol Genet**. 2006 Aug 1;15(15):2392-9

Wehler TC, Nonn M, Brandt B, Britten CM, Grone M, Todorova M, Link I, Khan SA, Meyer RG, Huber C, Hartwig UF, Herr W. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from anti-leukemic and anti-tumor donor T-cell lines. **Blood**. 2007 Jan 1;109(1):365-73.

Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wolfel C, Huber C, Wolfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. **Proc Natl Acad Sci U S A**. 2005 Nov 1;102(44):16013-8.

Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, Kobbe G, Bornhauser M, Hochhaus A, Ullmann AJ, Kindler T, Haus U, Gschaidmeier H, Huber C, Fischer T. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. **J Clin Oncol**. 2005 Oct 20;23(30):7583-93

Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, Brandts C, Serve H, Roesel J, Giles F, Feldman E, Ehninger G, Schiller GJ, Nimer S, Stone RM, Wang Y, Kindler T, Cohen PS, Huber C, Fischer T. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. **Blood**. 2006 Jan 1;107(1):293-300.

Britten CM, Meyer RG, Graf C, Huber C, Wolfel T. Identification of T cell epitopes by the use of rapidly generated mRNA fragments.

**J Immunol Methods.** 2005 Apr;299(1-2):165-75

Kuball J, Schmitz FW, Voss RH, Ferreira EA, Engel R, Guillaume P, Strand S, Romero P, Huber C, Sherman LA, Theobald M. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR.

**Immunity.** 2005, Jan;22(1):117-29

Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, Ehninger G, Schiller G, Klimek V, Nimer SD, Gratwohl A, Choudhary CR, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen PS, Huber C, Fischer T. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).

**Blood.** 2005 Jan 1;105(1):335-40.

Koslowski M, Bell C, Seitz G, Lehr HA, Roemer K, Muntefering H, Huber C, Sahin U, Tureci O. Frequent nonrandom activation of germ-line genes in human cancer.

**Cancer Res.** 2004 Sep 1;64(17):5988-93

Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, Ehninger G, Schiller G, Klimek V, Nimer SD, Gratwohl A, Choudhary C, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen PS, Huber C, Fischer T. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).

**Blood.** 2004 Sep 2

Doerschuck A, Schmidt A, Schnuerer E, Glueckmann M, Albrecht C, Woelfel C, Lennerz V, Lifke A, Di Natale C, Ranieri E, Gesualdo L, Huber C, Karas M, Woelfel T, Herr W. CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA-class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression.

**Blood.** 2004 Jul 1 [

Britten CM, Meyer RG, Frankenberg N, Huber C, Wolfel T. The use of clonal mRNA as an antigenic format for the detection of antigen-specific T lymphocytes in IFN-gamma ELISPOT assays.

**J Immunol Methods.** 2004 Apr;287(1-2):125-36.

Huber CH, Wolfel T. Immunotherapy of cancer: from vision to standard clinical practice.

**J Cancer Res Clin Oncol.** 2004 Apr 6

Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauff B, Duyster J, Peschel C, Kirkpatrick CJ, Theobald M, Gschaidmeier H, Huber C, Fischer T. The efficacy and safety of imatinib in adult patients with c-kit positive acute myeloid leukemia.

**Blood.** 2004 May 15;103(10):3644-54. May 15;103(10):3644-54.

Lotz C, Ferreira EA, Drexler I, Mutallib SA, Huber C, Sutter G, Theobald M. Partial tyrosinase-specific self tolerance by HLA-A\*0201-restricted cytotoxic T lymphocytes in mice and man.

**Int J Cancer.** 2004 Feb 10;108(4):571-579.

Krause P, Tureci O, Micke P, Buhl R, Huber C, Sahin U. SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity.  
**J Immunol Methods.** 2003 Dec;283(1-2):261-7.

Milosevic J, Hoffarth S, Huber C, Schuler M.  
The DNA damage-induced decrease of Bcl-2 is secondary to the activation of apoptotic effector caspases.  
**Oncogene.** 2003 Oct 9;22(44):6852-6

Kindler T, Breitenbuecher F, Kasper S, Stevens T, Carius B, Gschaidmeier H, Huber C, Fischer T. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.  
**Leukemia.** 2003 Jun;17(6):999-1009.

Kindler T, Breitenbuecher F, Marx A, Hess G, Gschaidmeier H, Gamm H, Kirkpatrick CJ, Huber C, Fischer T. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.  
**Blood.** 2003 Apr 15;101(8):2960-2.

Kuball J, Schuler M, Antunes Ferreira E, Herr W, Neumann M, Obenauer-Kutner L, Westreich L, Huber C, Wolfel T, Theobald M. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.  
**Gene Ther.** 2002 Jul;9(13):833-43

Hartwig UF, Robbers M, Wickenhauser C, Huber C. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death.  
**Blood.** 2002 Apr 15;99(8):3041-9.

Kuball J, Wen SF, Leissner J, Atkins D, Meinhardt P, Quijano E, Engler H, Hutchins B, Maneval DC, Grace MJ, Fritz MA, Storkel S, Thuroff JW, Huber C, Schuler M. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.  
**J Clin Oncol.** 2002 Feb 15;20(4):957-65

Stanislowski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, Kuball J, Ruppert T, Bolhuis RL, Melief CJ, Huber C, Stauss HJ, Theobald M. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.  
**Nature Immunol.** 2001 Oct;2(10):962-70.

Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ, Laufman L, Gralla R, Kuball J, Buhl R, Heussel CP, Kommos F, Perruchoud AP, Shepherd FA, Fritz MA, Horowitz JA, Huber C, Rochlitz C. Adenovirus-mediated wild-type p53 gene transfer in

patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.

**J Clin Oncol.** 2001 Mar 15;19(6):1750-8.

Lorenz J, Wilhelm K, Kessler M, Peschel C, Schwulera U, Lissner R, Struff WG, Huland E, Huber C, Aulitzky WE. Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects.

**Clin Cancer Res.** 1996 Jul;2(7):1115-22.

Schuler M, Rochlitz C, Horowitz JA, Schlegel J, Perruchoud AP, Kommos F, Bolliger CT, Kauczor HU, Dalquen P, Fritz MA, Swanson S, Herrmann R, Huber C. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer.

**Hum Gene Ther.** 1998 Sep 20;9(14):2075-82.

Theobald M, Ruppert T, Kuckelkorn U, Hernandez J, Haussler A, Ferreira EA, Liewer U, Biggs J, Levine AJ, Huber C, Koszinowski UH, Kloetzel PM, Sherman LA. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope.

**J Exp Med.** 1998 Sep 21;188(6):1017-28.

Aman MJ, Bug G, Aulitzky WE, Huber C, Peschel C. Inhibition of interleukin-11 by interferon-alpha in human bone marrow stromal cells.

**Exp Hematol.** 1996 Jul;24(8):863-7.

Aman MJ, Tretter T, Eisenbeis I, Bug G, Decker T, Aulitzky WE, Tilg H, Huber C, Peschel C. Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes.

**Blood.** 1996 Jun 1;87(11):4731-6.

Seliger B, Hohne A, Knuth A, Bernhard H, Meyer T, Tampe R, Momburg F, Huber C. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression.

**Cancer Res.** 1996 Apr 15;56(8):1756-60.

Fischer T, Aman J, van der Kuip H, Rudolf G, Peschel C, Aulitzky WE, Huber C. Induction of interferon regulatory factors 2'-5' oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness.

**Br J Haematol.** 1996 Mar;92(3):595-603.

Zissel G, Aulitzky WE, Lorenz J, Huber C, Muller-Quernheim J. Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2.

**Cancer Immunol Immunother.** 1996 Feb;42(2):122-6.



Decker T, Flohr T, Trautmann P, Aman MJ, Holter W, Majdic O, Huber C, Peschel C. Role of accessory cells in cytokine production by T cells in chronic B-cell lymphocytic leukemia. **Blood**. 1995 Aug 1;86(3):1115-23.

Weber M, Huber C. Complications and failures of subclavian-vein catheterization. **N Engl J Med**. 1995 Jun 8;332(23):1580

Aman MJ, Keller U, Derigs G, Mohamadzadeh M, Huber C, Peschel C. Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. **Blood**. 1994 Dec 15;84(12):4142-50.

Keller U, Aman MJ, Derigs G, Huber C, Peschel C. Human interleukin-4 enhances stromal cell-dependent hematopoiesis: costimulation with stem cell factor. **Blood**. 1994 Oct 1;84(7):2189-96.

Hladik F, Tratkiewicz JA, Tilg H, Vogel W, Schwulera U, Kronke M, Aulitzky WE, Huber C. Biologic activity of low dosage IL-2 treatment in vivo. Molecular assessment of cytokine network interaction. **J Immunol**. 1994 Aug 15;153(4):1449-54.

Aman MJ, Rudolf G, Goldschmitt J, Aulitzky WE, Lam C, Huber C, Peschel C. Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. **Blood**. 1993 Oct 15;82(8):2371-8.

Peschel C, Aman MJ, Rudolf G, Aulitzky WE, Huber C. Regulation of the cytokine network by interferon: a potential mechanism of interferon in chronic myelogenous leukemia. **Semin Hematol**. 1993 Jul;30(3 Suppl 3):28-31

Tilg H, Mier JW, Vogel W, Aulitzky WE, Wiedermann CJ, Vannier E, Huber C, Dinarello CA. Induction of circulating IL-1 receptor antagonist by IFN treatment. **J Immunol**. 1993 May 15;150(10):4687-92

Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, Huber C. Serum levels of cytokines in chronic liver diseases. **Gastroenterology**. 1992 Jul;103(1):264-74.

Irschick EU, Hladik F, Niederwieser D, Nussbaumer W, Holler E, Kaminski E, Huber C. Studies on the mechanism of tolerance or graft-versus-host disease in allogeneic bone marrow recipients at the level of cytotoxic T-cell precursor frequencies. **Blood**. 1992 Mar 15;79(6):1622-8.

Urba WJ, Kopp WC, Clark JW, Smith JW 2nd, Steis RG, Huber C, Coggin D, Longo DL. The in vivo immunomodulatory effects of recombinant interferon gamma plus recombinant tumor necrosis factor-alfa.

**J Clin Oncol.** 1991 Oct;9(10):1831-9.

Aulitzky WE, Tilg H, Vogel W, Aulitzky W, Berger M, Gastl G, Herold M, Huber C. Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2.

**Ann Hematol.** 1991 Feb;62(1):25-31.

Aulitzky WE, Tilg H, Gastl G, Mull R, Flener R, Vogel W, Herold M, Berger M, Judmaier G, Huber C. Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a phase I trial.

**Eur J Cancer.** 1991;27(4):462-7.

Niederwieser D, Herold M, Woloszczuk W, Aulitzky W, Meister B, Tilg H, Gastl G, Bowden R, Huber C.

Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages.

**Transplantation.** 1990 Oct;50(4):620-5.

Niederwieser DW, Appelbaum FR, Gastl G, Gersdorf E, Meister B, Geissler D, Tratkiewicz JA, Thaler J, Huber C. Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia.

**N Engl J Med.** 1990 Jun 21;322(25):1794-6.

Gastl G, Aulitzky W, Tilg H, Thaler J, Berger M, Huber C. Minimal interferon-alpha doses for hairy cell leukemia.

**Blood.** 1990 Feb 1;75(3):812-3

Irschick E, Miller K, Berger M, Schonitzer D, Koller J, Wagner H, Gottinger W, Huber C. Studies of the mechanism of tolerance induced by short-term immunosuppression with cyclosporine in high-risk corneal allograft recipients. I. Analysis of CTL precursor frequencies.

**Transplantation.** 1989 Dec;48(6):986-90.

Aulitzky W, Gastl G, Aulitzky WE, Herold M, Kemmler J, Mull B, Frick J, Huber C. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

**J Clin Oncol.** 1989 Dec;7(12):1875-84.

Hinterberger W, Adolf G, Bettelheim P, Geissler K, Huber C, Irschick E, Kalhs P, Koller U, Lechner K, Meister B, et al. Lymphokine overproduction in severe aplastic anemia is not related to blood transfusions.

**Blood.** 1989 Dec;74(8):2713-7.

Aulitzky WE, Tilg H, Niederwieser D, Hackl M, Meister B, Huber C. Ganciclovir and hyperimmunoglobulin for treating cytomegalovirus infection in bone marrow transplant recipients.

**J Infect Dis.** 1988 Aug;158(2):488-9

Hinterberger W, Adolf G, Aichinger G, Dudczak R, Geissler K, Hocker P, Huber C, Kalhs P, Knapp W, Koller U, et al. Further evidence for lymphokine overproduction in severe aplastic anemia.

**Blood.** 1988 Jul;72(1):266-72.

Miller K, Huber C, Niederwieser D, Gottinger W. Successful engraftment of high-risk corneal allografts with short-term immunosuppression with cyclosporine.

**Transplantation.** 1988 Mar;45(3):651-3.

Gastl G, Aulitzky W, Margreiter R, Flener R, Van Camp B, Bememan Z, Peetermans M, Huber C. Recombinant alpha 2 interferon for induction and maintenance of remission in hairy cell leukaemia.

**Br J Haematol.** 1985 Nov;61(3):581-2

Aubock J, Irschick E, Romani N, Kompatscher P, Hopfl R, Herold M, Schuler G, Bauer M, Huber C, Fritsch P.

Rejection, after a slightly prolonged survival time, of Langerhans cell-free allogeneic cultured epidermis used for wound coverage in humans.

**Transplantation.** 1988 Apr;45(4):730-7.

Miller K, Huber C, Niederwieser D, Gottinger W. Successful engraftment of high-risk corneal allografts with short-term immunosuppression with cyclosporine.

**Transplantation.** 1988 Mar;45(3):651-3.

Aulitzky W, Gastl G, Aulitzky WE, Nachbaur K, Lanske B, Kemmler G, Flener R, Frick J, Huber C. Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses.

**Immunobiology.** 1987 Dec;176(1-2):85-95.

Schoedon G, Troppmair J, Fontana A, Huber C, Curtius HC, Niederwieser A. Biosynthesis and metabolism of pterins in peripheral blood mononuclear cells and leukemia lines of man and mouse.

**Eur J Biochem.** 1987 Jul 15;166(2):303-10.

Huber C, Aulitzky W, Tilg H, von Luttichau I, Troppmair J, Nachbauer K, Gastl G. Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell

leukemia.

**Leukemia.** 1987 Apr;1(4):355-7.

Herzog WR, Zanker B, Irschick E, Huber C, Franz HE, Wagner H, Kabelitz D. Selective reduction of donor-specific cytotoxic T lymphocyte precursors in patients with a well-functioning kidney allograft.

**Transplantation.** 1987 Mar;43(3):384-9.

Margreiter R, Niederwieser D, Frommhold H, Schonitzer D, Gratwohl A, Huber C. Tumor recurrence after liver transplantation followed by high-dose cyclophosphamide, total body irradiation, and autologous bone marrow transplantation for treatment of metastatic liver disease.

**Transplant Proc.** 1987 Feb;19(1 Pt 3):2403-4

Berneman ZN, Gastl G, Gangji D, van Camp B, Jochmans K, Aulitzky W, Flament J, Peetermans ME, Huber C. Treatment of hairy-cell leukemia with recombinant alpha 2-interferon.

**Eur J Cancer Clin Oncol.** 1986 Aug;22(8):987-90.

Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J, Wachter H. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.

**J Exp Med.** 1984 Jul 1;160(1):310-6.

Huber C, Fuchs D, Hausen A, Margreiter R, Reibnegger G, Spielberger M, Wachter H. Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants.

**J Immunol.** 1983 Mar;130(3):1047-50

Huber C, Merckenschlager M, Gattringer C, Royston I, Fink U, Braunsteiner H. Human autologous mixed lymphocyte reactivity is primarily specific for xenoprotein determinants adsorbed to antigen-presenting cells during rosette formation with sheep erythrocytes.

**J Exp Med.** 1982 Apr 1;155(4):1222-7.

Zier KS, Huber C, Albert E, Braunsteiner H. Cell-mediated immune responses between HLA-identical siblings: recognition of antigenic changes associated with acute myelogenous leukaemia.

**Clin Exp Immunol.** 1980 Apr;40(1):136-46.

Huber C, Rodt H, Thierfelder S, Braunsteiner H. Surface properties and in vitro functional capacities of human T lymphocyte subsets separated by linear density gradients.

**J Immunol.** 1979 Jul;123(1):405-11.

Huber C, Michlmayr G, Falkensamer M, Fink U, Zur Nedden G, Braunsteiner H, Huber H. Increased proliferation of T lymphocytes in the blood of patients with Hodgkin's disease. **Clin Exp Immunol.** 1975 Jul;21(1):47-53.

Huber C, Huber H, Schmalzl F, Braunsteiner H. Decreased proliferative activity of erythroblasts in granulocytic stem cell leukemia. **Nature.** 1971 Jan 8;229(5280):113-4.